Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Lisa A. Jackson; Alejandra Gurtman; Kathryn Rice; Karlis Pauksens; Richard N. Greenberg; Thomas R. Jones; Daniel A. Scott; Emilio A. Emini; William C. Gruber; Beate Schmoele-Thoma

doi:10.1016/j.vaccine.2013.05.010

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, Karlis Pauksens, Richard N. Greenberg, Thomas R. Jones, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmoele-Thoma

Internal Medicine

Research output: Contribution to journal › Article › peer-review

161 Scopus citations

Abstract

Background: The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide extended protection into older age. This reflects a significant unmet medical need for alternative strategies to protect older adults against pneumococcal infection, which may be met by the 13-valent polysaccharide conjugate vaccine (PCV13). Methods: We performed a randomized, modified double-blind trial in 936 adults aged 70 years and older who had previously received PPSV23 at least 5 years before study entry and were now vaccinated with PCV13 or PPSV23. At 1 year after enrollment, all subjects received a follow-on dose of PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and at 1 month after each vaccination. Results: Following the enrollment vaccination, OPA titers were significantly greater in the PCV13 group compared to the PPSV23 group for 10 of the 12 serotypes common to both vaccines and to serotype 6A which is unique to PCV13. Responses were noninferior for the other 2 common serotypes. Responses to PCV13 given at 1 year were generally lower in the group that received PPSV23 at enrollment. Conclusion: In adults aged 70 years and older previously vaccinated with PPSV23, PCV13 was significantly more immunogenic than PPSV23 for most of the common serotypes and for serotype 6A. The OPA responses after a follow-on dose of PCV13 one year later indicate that a prior dose of PPSV23, but not PCV13, diminishes the response to the subsequent administration of PCV13.

Original language	English
Pages (from-to)	3585-3593
Number of pages	9
Journal	Vaccine
Volume	31
Issue number	35
DOIs	https://doi.org/10.1016/j.vaccine.2013.05.010
State	Published - Aug 2 2013

Bibliographical note

Funding Information:
This study was funded by Wyeth Vaccines Research , which was acquired by Pfizer Inc. in October 2009. The sponsor and all authors were involved in the study design and the data collection, analysis, and interpretation of data, writing of the manuscript and in the decision to submit the manuscript for publication.

Funding Information:
AG, TRJ, DAS, EAE, WCG, and BS-T are current employees of Pfizer and may hold stock options. LAJ, KR, KP, and RNG received funding from Pfizer to conduct this study. LAJ received support from Pfizer for attendance at a scientific meeting. The Group Health Research Institute has received grants from Pfizer, Novartis, Inviragen, Sanofi-Pasteur, the National Institutes for Health and the Centers for Disease Control and Prevention. The Minneapolis VA Medical Center was supported in part by the research service of the Minneapolis VA Health Care Service. Uppsala University has received research grants from Pfizer, GlaxoSmithKline, Eurocine and Sanofi-Pasteur. RNG received support from Pfizer for attendance at a scientific meeting. The University of Kentucky was supported in part by an National Institutes for Health research grant to their Aging Center, and has received research grants from Viropharma, T2, PaxVax and Bavarian-Nordic.

Funding

This study was funded by Wyeth Vaccines Research , which was acquired by Pfizer Inc. in October 2009. The sponsor and all authors were involved in the study design and the data collection, analysis, and interpretation of data, writing of the manuscript and in the decision to submit the manuscript for publication. AG, TRJ, DAS, EAE, WCG, and BS-T are current employees of Pfizer and may hold stock options. LAJ, KR, KP, and RNG received funding from Pfizer to conduct this study. LAJ received support from Pfizer for attendance at a scientific meeting. The Group Health Research Institute has received grants from Pfizer, Novartis, Inviragen, Sanofi-Pasteur, the National Institutes for Health and the Centers for Disease Control and Prevention. The Minneapolis VA Medical Center was supported in part by the research service of the Minneapolis VA Health Care Service. Uppsala University has received research grants from Pfizer, GlaxoSmithKline, Eurocine and Sanofi-Pasteur. RNG received support from Pfizer for attendance at a scientific meeting. The University of Kentucky was supported in part by an National Institutes for Health research grant to their Aging Center, and has received research grants from Viropharma, T2, PaxVax and Bavarian-Nordic.

Funders	Funder number
Eurocine and Sanofi-Pasteur
Inviragen
Minneapolis VA Health Care Service
Sanofi Pasteur
Wyeth Vaccines Research
Foundation for the National Institutes of Health
Centers for Disease Control and Prevention
Pfizer
Novartis
North Carolina GlaxoSmithKline Foundation
ViroPharma Inc
Uppsala Universitet

Keywords

Adults
PCV13
Pneumococcal conjugate vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2013.05.010

Cite this

Jackson, L. A., Gurtman, A., Rice, K., Pauksens, K., Greenberg, R. N., Jones, T. R., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2013). Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine, 31(35), 3585-3593. https://doi.org/10.1016/j.vaccine.2013.05.010

@article{fdab903e9fb14ef595b0a678c3eeae45,

title = "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine",

abstract = "Background: The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide extended protection into older age. This reflects a significant unmet medical need for alternative strategies to protect older adults against pneumococcal infection, which may be met by the 13-valent polysaccharide conjugate vaccine (PCV13). Methods: We performed a randomized, modified double-blind trial in 936 adults aged 70 years and older who had previously received PPSV23 at least 5 years before study entry and were now vaccinated with PCV13 or PPSV23. At 1 year after enrollment, all subjects received a follow-on dose of PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and at 1 month after each vaccination. Results: Following the enrollment vaccination, OPA titers were significantly greater in the PCV13 group compared to the PPSV23 group for 10 of the 12 serotypes common to both vaccines and to serotype 6A which is unique to PCV13. Responses were noninferior for the other 2 common serotypes. Responses to PCV13 given at 1 year were generally lower in the group that received PPSV23 at enrollment. Conclusion: In adults aged 70 years and older previously vaccinated with PPSV23, PCV13 was significantly more immunogenic than PPSV23 for most of the common serotypes and for serotype 6A. The OPA responses after a follow-on dose of PCV13 one year later indicate that a prior dose of PPSV23, but not PCV13, diminishes the response to the subsequent administration of PCV13.",

keywords = "Adults, PCV13, Pneumococcal conjugate vaccine",

author = "Jackson, {Lisa A.} and Alejandra Gurtman and Kathryn Rice and Karlis Pauksens and Greenberg, {Richard N.} and Jones, {Thomas R.} and Scott, {Daniel A.} and Emini, {Emilio A.} and Gruber, {William C.} and Beate Schmoele-Thoma",

note = "Funding Information: This study was funded by Wyeth Vaccines Research , which was acquired by Pfizer Inc. in October 2009. The sponsor and all authors were involved in the study design and the data collection, analysis, and interpretation of data, writing of the manuscript and in the decision to submit the manuscript for publication. Funding Information: AG, TRJ, DAS, EAE, WCG, and BS-T are current employees of Pfizer and may hold stock options. LAJ, KR, KP, and RNG received funding from Pfizer to conduct this study. LAJ received support from Pfizer for attendance at a scientific meeting. The Group Health Research Institute has received grants from Pfizer, Novartis, Inviragen, Sanofi-Pasteur, the National Institutes for Health and the Centers for Disease Control and Prevention. The Minneapolis VA Medical Center was supported in part by the research service of the Minneapolis VA Health Care Service. Uppsala University has received research grants from Pfizer, GlaxoSmithKline, Eurocine and Sanofi-Pasteur. RNG received support from Pfizer for attendance at a scientific meeting. The University of Kentucky was supported in part by an National Institutes for Health research grant to their Aging Center, and has received research grants from Viropharma, T2, PaxVax and Bavarian-Nordic. ",

year = "2013",

month = aug,

day = "2",

doi = "10.1016/j.vaccine.2013.05.010",

language = "English",

volume = "31",

pages = "3585--3593",

number = "35",

}

Jackson, LA, Gurtman, A, Rice, K, Pauksens, K, Greenberg, RN, Jones, TR, Scott, DA, Emini, EA, Gruber, WC & Schmoele-Thoma, B 2013, 'Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine', Vaccine, vol. 31, no. 35, pp. 3585-3593. https://doi.org/10.1016/j.vaccine.2013.05.010

TY - JOUR

T1 - Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

AU - Jackson, Lisa A.

AU - Gurtman, Alejandra

AU - Rice, Kathryn

AU - Pauksens, Karlis

AU - Greenberg, Richard N.

AU - Jones, Thomas R.

AU - Scott, Daniel A.

AU - Emini, Emilio A.

AU - Gruber, William C.

AU - Schmoele-Thoma, Beate

N1 - Funding Information: This study was funded by Wyeth Vaccines Research , which was acquired by Pfizer Inc. in October 2009. The sponsor and all authors were involved in the study design and the data collection, analysis, and interpretation of data, writing of the manuscript and in the decision to submit the manuscript for publication. Funding Information: AG, TRJ, DAS, EAE, WCG, and BS-T are current employees of Pfizer and may hold stock options. LAJ, KR, KP, and RNG received funding from Pfizer to conduct this study. LAJ received support from Pfizer for attendance at a scientific meeting. The Group Health Research Institute has received grants from Pfizer, Novartis, Inviragen, Sanofi-Pasteur, the National Institutes for Health and the Centers for Disease Control and Prevention. The Minneapolis VA Medical Center was supported in part by the research service of the Minneapolis VA Health Care Service. Uppsala University has received research grants from Pfizer, GlaxoSmithKline, Eurocine and Sanofi-Pasteur. RNG received support from Pfizer for attendance at a scientific meeting. The University of Kentucky was supported in part by an National Institutes for Health research grant to their Aging Center, and has received research grants from Viropharma, T2, PaxVax and Bavarian-Nordic.

PY - 2013/8/2

Y1 - 2013/8/2

N2 - Background: The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide extended protection into older age. This reflects a significant unmet medical need for alternative strategies to protect older adults against pneumococcal infection, which may be met by the 13-valent polysaccharide conjugate vaccine (PCV13). Methods: We performed a randomized, modified double-blind trial in 936 adults aged 70 years and older who had previously received PPSV23 at least 5 years before study entry and were now vaccinated with PCV13 or PPSV23. At 1 year after enrollment, all subjects received a follow-on dose of PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and at 1 month after each vaccination. Results: Following the enrollment vaccination, OPA titers were significantly greater in the PCV13 group compared to the PPSV23 group for 10 of the 12 serotypes common to both vaccines and to serotype 6A which is unique to PCV13. Responses were noninferior for the other 2 common serotypes. Responses to PCV13 given at 1 year were generally lower in the group that received PPSV23 at enrollment. Conclusion: In adults aged 70 years and older previously vaccinated with PPSV23, PCV13 was significantly more immunogenic than PPSV23 for most of the common serotypes and for serotype 6A. The OPA responses after a follow-on dose of PCV13 one year later indicate that a prior dose of PPSV23, but not PCV13, diminishes the response to the subsequent administration of PCV13.

AB - Background: The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide extended protection into older age. This reflects a significant unmet medical need for alternative strategies to protect older adults against pneumococcal infection, which may be met by the 13-valent polysaccharide conjugate vaccine (PCV13). Methods: We performed a randomized, modified double-blind trial in 936 adults aged 70 years and older who had previously received PPSV23 at least 5 years before study entry and were now vaccinated with PCV13 or PPSV23. At 1 year after enrollment, all subjects received a follow-on dose of PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and at 1 month after each vaccination. Results: Following the enrollment vaccination, OPA titers were significantly greater in the PCV13 group compared to the PPSV23 group for 10 of the 12 serotypes common to both vaccines and to serotype 6A which is unique to PCV13. Responses were noninferior for the other 2 common serotypes. Responses to PCV13 given at 1 year were generally lower in the group that received PPSV23 at enrollment. Conclusion: In adults aged 70 years and older previously vaccinated with PPSV23, PCV13 was significantly more immunogenic than PPSV23 for most of the common serotypes and for serotype 6A. The OPA responses after a follow-on dose of PCV13 one year later indicate that a prior dose of PPSV23, but not PCV13, diminishes the response to the subsequent administration of PCV13.

KW - Adults

KW - PCV13

KW - Pneumococcal conjugate vaccine

UR - http://www.scopus.com/inward/record.url?scp=84880723200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880723200&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.05.010

DO - 10.1016/j.vaccine.2013.05.010

M3 - Article

C2 - 23688527

AN - SCOPUS:84880723200

SN - 0264-410X

VL - 31

SP - 3585

EP - 3593

JO - Vaccine

JF - Vaccine

IS - 35

ER -

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this